---
figid: PMC6142530__bloodbook-2017-460-g001
figtitle: Novel agents and pathways under investigation in MDS
organisms:
- NA
pmcid: PMC6142530
filename: bloodbook-2017-460-g001.jpg
figlink: /pmc/articles/PMC6142530/figure/F1/
number: F1
caption: Novel agents and pathways under investigation in MDS. Epigenetic modulators
  including HMA, HDACis, BET inhibitors, and LSD1i affect chromatin structure and
  transcription; immune checkpoint inhibition with a variety of monoclonal antibodies
  targeting the PD-1/PDL1 interaction, or CTLA-4 and its corresponding ligand facilitate
  antigen (MHC) recognition by T-cell receptors; IDH1/2 inhibition affects the mutant
  enzyme within mitochondria, splicing modulation acts preferentially on cells harboring
  mutations in splicing factors (splice mut); kinase inhibitors downregulate key signaling
  pathways including the RAS/MAPK and the PI3-K/AKT/m-TOR pathway.
papertitle: Incorporating novel approaches in the management of MDS beyond conventional
  hypomethylating agents.
reftext: Olatoyosi Odenike. Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):460-469.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9582207
figid_alias: PMC6142530__F1
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC6142530__F1
ndex: 3480ad19-dee0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6142530__bloodbook-2017-460-g001.html
  '@type': Dataset
  description: Novel agents and pathways under investigation in MDS. Epigenetic modulators
    including HMA, HDACis, BET inhibitors, and LSD1i affect chromatin structure and
    transcription; immune checkpoint inhibition with a variety of monoclonal antibodies
    targeting the PD-1/PDL1 interaction, or CTLA-4 and its corresponding ligand facilitate
    antigen (MHC) recognition by T-cell receptors; IDH1/2 inhibition affects the mutant
    enzyme within mitochondria, splicing modulation acts preferentially on cells harboring
    mutations in splicing factors (splice mut); kinase inhibitors downregulate key
    signaling pathways including the RAS/MAPK and the PI3-K/AKT/m-TOR pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tcr
  - Prosbeta7
  - ras
  - Ras64B
  - Ras85D
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Idh
  - Mtor
  - Tor
  - Erk7
  - rl
  - bet
  - TRBV20OR9-2
  - TRA
  - TRB
  - TRD
  - TRG
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - CTLA4
  - CD274
  - KRAS
  - HRAS
  - NRAS
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - IDH1
  - IDH2
  - MTOR
  - EPHB2
  - MAPK1
  - MAPK3
  - HDAC1
  - HDAC2
  - HDAC3
  - HDAC8
  - DNER
  - MMUT
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
